Semax vs Selank: Same Russian Lab, Different Mechanisms, One Clear Stack Logic

Semax is a synthetic heptapeptide analog of ACTH(4-7) - specifically, the fragment Met-Glu-His-Phe-Pro-Gly-Pro. It was developed by the Institute of Molecular Genetics at the Russian Academy of Sciences and has been used clinically in Russia since 1991 for stroke recovery, cognitive enhancement, and neuroprotection. Its primary mechanisms are BDNF (brain-derived neurotrophic factor) upregulation, enhancement of dopaminergic and serotonergic tone, and modulation of the melanocortin system. In rodent studies, a single intranasal dose produces measurable BDNF elevation within 24 hours, with effects on learning and memory that persist for 3-5 days post-administration.

The subjective cognitive profile of Semax in human research subjects tends toward improved focus, information processing speed, and working memory, with a mildly stimulating quality that most users describe as cleaner than caffeine - no jitteriness, but elevated alertness. This stimulatory component makes AM dosing preferable for most protocols; evening dosing can interfere with sleep architecture in sensitive individuals.

Selank is a synthetic hexapeptide analog of tuftsin (Thr-Lys-Pro-Arg) with a Gly-Gly extension that improves stability. It was developed at the same institute as Semax and has been used clinically in Russia for generalized anxiety disorder and phobic states. Its primary mechanism is modulation of the GABAergic system - Selank appears to enhance the expression and activity of GABA-A receptors without the receptor downregulation or tolerance development that defines benzodiazepine action. It also modulates enkephalin metabolism, increasing levels of endogenous anxiolytic neuropeptides.

The resulting pharmacological profile is anxiolysis without sedation - reduced anxiety and improved stress resilience without the cognitive blunting associated with benzodiazepines or the rebound anxiety that follows their discontinuation. This makes Selank particularly valuable in research contexts where the goal is anxiolysis that does not impair the cognitive work the researcher is trying to support.

Both compounds are typically delivered intranasally using a nasal spray bottle or direct pipette. The critical calculation for intranasal delivery is concentration per actuation - a standard nasal spray delivers approximately 0.1mL per spray. If your Semax solution is 750 mcg/mL (5mg vial in 6.67mL saline), each spray delivers approximately 75 mcg. If it is 1500 mcg/mL (5mg in 3.33mL), each spray delivers 150 mcg. Getting this math right is essential because unlike subcutaneous injection, intranasal dosing has no visual confirmation of volume delivered.

Standard cycle length for both compounds is 2-4 weeks on, 1-2 weeks off. Some Russian clinical protocols run up to 10-14 days and repeat quarterly. Selank has a lower tolerance-development risk than Semax due to its non-dopaminergic mechanism, so some researchers run Selank continuously while cycling Semax. The intranasal route for both offers rapid onset (15-30 minutes to peak effect) due to direct olfactory pathway absorption.